Thus, to delineate the pivotal cellular mediators underlying the antitumor efficacy of the combined therapeutic regimen, we utilized the LLC tumor rechallenge murine model to systematically deplete NK cells, CD4+ and CD8+ T cells, enabling the assessment of their distinct roles in the antitumor response (Figure 2I). This evidence concerns the gene CD8A and neoplasm.